Immuron Limited · ASX:IMC

Immuron — Coffee Microcaps (October 2024)

13 slides from Immuron's conference presentation, Oct 22, 2024

  1. Slide 1: Coffee Microcaps

    Slide 1: Coffee Microcaps

    NASDAQ: IMRN ASX: IMC Coffee Microcaps Steven Lydeamore Chief Executive Officer 22 October 2024

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i c i p a t e

  3. Slide 3: Executive summary

    Slide 3: Executive summary

    Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview Financial Snapshot Two commercially available oral immunotherapeuti

  4. Slide 4: Opportunity to Convert Billion Dollar Traveller's Diarrhoea Market from Relief to Prevention by Travelan

    Slide 4: Opportunity to Convert Billion Dollar Traveller's Diarrhoea Market from Relief to Prevention by Travelan

    Opportunity to Convert Billion Dollar Traveller’s Diarrhoea Market from Relief to Prevention by Travelan® Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7%1 Industry tailwinds International travel continues to grow Travel to high-risk destinations fro

  5. Slide 5: Travelan continued strong sales growth

    Slide 5: Travelan continued strong sales growth

    Travelan® continued strong sales growth Global + Q1 FY2025 AUD$1.5 million up 13% on prior quarter Australia + Q1 2025 AUD$1.0 million up 3% on prior quarter + Secured core ranging in another nine pharmacy banner groups North America + Q1 2025 AUD$0.5 million up 48% on prior quarter + Strongest mont

  6. Slide 6: Status of product portfolio and key milestones

    Slide 6: Status of product portfolio and key milestones

    Status of product portfolio and key milestones Travelan® Clostridioides difficile MTEC 21-10-013 grant Phase 2 IMM-529 Immuron’s Clinical Programs randomized clinical challenge study to Prevention of recurrent CDI infections Compound or examine a dosing regimen for Travelan® Vaccine (spores, vegetat

  7. Slide 7: Opportunity Assessment for IMM-124E and IMM-529

    Slide 7: Opportunity Assessment for IMM-124E and IMM-529

    IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT Updated Revenue Estimate for IMM-52 up from US$93 million to ~US$400 million › Immuron’s development of IMM-124E (hyperimmune › Infectious disease experts reacted favorably to the IMM-529 bovine colostrum) as a prescription medication has MOA, and

  8. Slide 8: World First Triple Mechanism of Action for CDI

    Slide 8: World First Triple Mechanism of Action for CDI

    WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024; successful pre-IND meeting Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile Population infection Product • Novel antibody-containing therapeutic which neutralizes C. dif

  9. Slide 9: Positive results support Travelan progress to phase 3

    Slide 9: Positive results support Travelan progress to phase 3

    Positive results support Travelan® progress to phase 3 IMM-124E Phase 2 + Healthy volunteers were recruited and randomized to receive a single daily oral Travelan® topline clinical dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days prior to trial results demonstrate challenge with ETEC

  10. Slide 10: IMM-124E Phase 3 strategy

    Slide 10: IMM-124E Phase 3 strategy

    IMM-124E Phase 3 strategy Pre 2H 2024 1H 2025 2H 2025 Post Phase 1 clinical study Additional topline data Clinical Study Report Initiate Phase 3 Trial duration ~ 2 years (Baltimore, 1996) analysis August 2024 anticipated October 2024 End of Phase 3 FDA meeting Phase 2 clinical study End of Phase 2 F

  11. Slide 11: Upcoming Milestones

    Slide 11: Upcoming Milestones

    Upcoming Milestones Revenue + Continued quarter on quarter growth from growth drivers + Secured core ranging in another nine Australian pharmacy banner groups + Strongest monthly sales on amazon.com in September 2024 + Secured distribution in ten pharmacy/grocery retailers in Canada Clinical IMM-124

  12. Slide 12: Scientific references

    Slide 12: Scientific references

    Scientific references Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of Travelan® an Oral Pro

  13. Slide 13: Steven Lydeamore, Chief Executive Officer, Immuron Limited

    Slide 13: Steven Lydeamore, Chief Executive Officer, Immuron Limited

    STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: [email protected] PHONE: AUSTRALIA: +61 438 027 172

Source: Internet Archive copy of immuron.com.au

More decks from Immuron Limited

All 112 Immuron decks